Physician profile
Ronald E Wilson
NPI 1497749568
$29,631.14
in general payments reported to CMS, 2019-2025
59 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $978 · 2021: $1,521 · 2022: $1,214 · 2023: $1,220 · 2024: $36.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.27 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $11,357.78 | 2019-2022 | |
| Lilly USA, LLC | $7,218.47 | 2019-2023 | Reyvow, Emgality |
| Novartis Pharmaceuticals Corporation | $4,460.61 | 2019-2023 | |
| Biogen, INC. | $837.63 | 2019-2024 | Tysabri, Vumerity, Plegridy |
| Amgen INC. | $711.64 | 2019-2023 | Aimovig |
| Genzyme Corporation | $541.19 | 2019-2023 | |
| Emd Serono, INC. | $446.70 | 2019-2023 | Mavenclad |
| Abbvie INC. | $397.39 | 2019-2023 | Ubrelvy, Qulipta, Botox |
| Sunovion Pharmaceuticals INC. | $320.30 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $225.25 | 2019-2023 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $221.30 | 2020-2023 | Ongentys, Ingrezza |
| Janssen Pharmaceuticals, INC | $206.40 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $205.99 | 2019-2022 | |
| Ucb, INC. | $175.23 | 2019-2023 | |
| Lundbeck LLC | $155.87 | 2019-2023 | Vyepti |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.